GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Cyclically Adjusted Revenue per Share

Nanomix (Nanomix) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nanomix's adjusted revenue per share data for the fiscal year that ended in Dec. 2022 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-22), Nanomix's current stock price is $ 0.0001. Nanomix's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2022 was $0.00. Nanomix's Cyclically Adjusted PS Ratio of today is .


Nanomix Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Nanomix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Cyclically Adjusted Revenue per Share Chart

Nanomix Annual Data
Trend Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
- - -

Nanomix Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nanomix's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Nanomix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanomix's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nanomix's Cyclically Adjusted PS Ratio falls into.



Nanomix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanomix's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2022 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=0/125.2218*125.2218
=0.000

Current CPI (Dec. 2022) = 125.2218.

Nanomix does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate it.


Nanomix  (OTCPK:NNMX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nanomix Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Nanomix's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanomix (Nanomix) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338

Nanomix (Nanomix) Headlines

From GuruFocus

Nanomix Initiates New Clinical Study for the eLab S1 Panel

By GuruFocusNews GuruFocusNews 07-02-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By GuruFocusNews GuruFocusNews 06-24-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 07-02-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 06-15-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 06-22-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By GuruFocusNews GuruFocusNews 07-04-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By PurpleRose PurpleRose 07-12-2022